Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1082) 1082
Publication (92) 92
Book Review (21) 21
Book Chapter (5) 5
Conference Proceeding (4) 4
Data Set (2) 2
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (833) 833
topotecan (803) 803
oncology (662) 662
female (549) 549
male (415) 415
index medicus (357) 357
middle aged (329) 329
adult (325) 325
topotecan - administration & dosage (318) 318
aged (313) 313
cancer (303) 303
animals (295) 295
pharmacology & pharmacy (284) 284
chemotherapy (279) 279
pharmacokinetics (274) 274
topotecan - pharmacokinetics (265) 265
camptothecin - analogs & derivatives (257) 257
antineoplastic agents - pharmacokinetics (245) 245
neoplasms - drug therapy (200) 200
antineoplastic agents - administration & dosage (191) 191
camptothecin (191) 191
mice (190) 190
antineoplastic combined chemotherapy protocols - therapeutic use (187) 187
antineoplastic agents - therapeutic use (175) 175
phase-i (172) 172
camptothecin - pharmacokinetics (160) 160
topotecan - adverse effects (157) 157
drug administration schedule (154) 154
topotecan - therapeutic use (146) 146
dose-response relationship, drug (145) 145
treatment outcome (145) 145
irinotecan (135) 135
solid tumors (134) 134
antineoplastic agents - adverse effects (130) 130
infusions, intravenous (123) 123
cisplatin (120) 120
ovarian neoplasms - drug therapy (114) 114
camptothecin - administration & dosage (112) 112
topoisomerase i inhibitors (112) 112
topotecan - pharmacology (112) 112
antineoplastic agents - pharmacology (111) 111
lung neoplasms - drug therapy (110) 110
medicine & public health (110) 110
cell line, tumor (104) 104
child (104) 104
paclitaxel (103) 103
topoisomerase-i (102) 102
cell lung-cancer (100) 100
administration, oral (99) 99
phase-ii (96) 96
care and treatment (95) 95
camptothecin - therapeutic use (94) 94
antineoplastic combined chemotherapy protocols - adverse effects (93) 93
trial (92) 92
pharmacodynamics (89) 89
pharmacology/toxicology (89) 89
adolescent (87) 87
research (86) 86
tumors (85) 85
child, preschool (84) 84
toxicity (84) 84
area under curve (83) 83
drug resistance, neoplasm (83) 83
children (82) 82
antineoplastic agents (81) 81
ovarian cancer (81) 81
camptothecin - pharmacology (80) 80
camptothecin - adverse effects (76) 76
antimitotic agents (75) 75
xenografts (74) 74
antineoplastic combined chemotherapy protocols - administration & dosage (73) 73
maximum tolerated dose (72) 72
atp binding cassette transporter, sub-family g, member 2 (71) 71
dna topoisomerase-i (70) 70
neoplasm recurrence, local - drug therapy (70) 70
carboplatin (69) 69
carcinoma (69) 69
drug therapy (69) 69
combination (68) 68
antitumor-activity (67) 67
aged, 80 and over (65) 65
analysis (65) 65
multidrug-resistance (65) 65
hematology (64) 64
neoplasms - metabolism (64) 64
etoposide (63) 63
antineoplastic combined chemotherapy protocols - pharmacokinetics (61) 61
article (59) 59
bioavailability (59) 59
drugs (58) 58
topoisomerase-i inhibitor (58) 58
cpt-11 (57) 57
doxorubicin (57) 57
oral topotecan (57) 57
p-glycoprotein (57) 57
expression (55) 55
rats (54) 54
therapy (54) 54
cisplatin - administration & dosage (53) 53
clinical trials (53) 53
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1072) 1072
Japanese (7) 7
French (6) 6
German (4) 4
Italian (4) 4
Chinese (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect
by Bocci, Guido and Kerbel, Robert S
Nature Reviews Clinical Oncology, ISSN 1759-4774, 11/2016, Volume 13, Issue 11, pp. 659 - 673
Metronomic chemotherapy describes the close, regular administration of chemotherapy drugs at less-toxic doses over prolonged periods of time. In 2015, the... 
IN-VITRO | ANTIANGIOGENIC ACTIVITY | ONCOLOGY | RANDOMIZED PHASE-II | BREAST-CANCER PATIENTS | ANTITUMOR INNATE IMMUNITY | ORAL TOPOTECAN | CYCLOPHOSPHAMIDE TREATMENT | ANTICANCER DRUGS | CLINICAL PHARMACOKINETICS | DOSE CHEMOTHERAPY | Angiogenesis Inhibitors - immunology | Pyrimidines - immunology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Breast Neoplasms - immunology | Alkylating Agents - immunology | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Angiogenesis Inhibitors - administration & dosage | Clinical Trials, Phase III as Topic | Colorectal Neoplasms - drug therapy | Tubulin Modulators - administration & dosage | Alkylating Agents - pharmacokinetics | Camptothecin - administration & dosage | Female | Camptothecin - immunology | Camptothecin - pharmacokinetics | Pyrimidines - administration & dosage | Tubulin Modulators - pharmacokinetics | Alkylating Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - immunology | Breast Neoplasms - drug therapy | Forecasting | Randomized Controlled Trials as Topic | Immunity, Cellular - immunology | Colorectal Neoplasms - immunology | Tubulin Modulators - immunology | Pyrimidines - pharmacokinetics | Chemotherapy | Care and treatment | Patient outcomes | Forecasts and trends | Pharmacokinetics | Observations | Methods | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
by Lin Zhou and Kari Schmidt and Frederick R. Nelson and Veronica Zelesky and Matthew D. Troutman and Bo Feng
Drug Metabolism and Disposition, ISSN 0090-9556, 05/2009, Volume 37, Issue 5, pp. 946 - 955
The role of breast cancer resistance protein (Bcrp) and the combined activities of Bcrp and P-glycoprotein (P-gp, Mdr1a/1b) in limiting the brain penetration... 
TRANSPORT | EFFLUX | MITOXANTRONE | MOUSE | BARRIER | TOPOTECAN | DRUGS | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | EXPOSURE | ABCG2 | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Chromatography, High Pressure Liquid | Blood Proteins - metabolism | ATP-Binding Cassette Transporters - physiology | Brain - metabolism | ATP-Binding Cassette Transporters - genetics | Mass Spectrometry | Prazosin - pharmacokinetics | Piperidines - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Adrenergic alpha-Antagonists - pharmacokinetics | Piperazines - pharmacokinetics | Cell Line | Oxazoles - pharmacokinetics | Propionates - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - physiology | Flavonoids - pharmacokinetics | Imatinib Mesylate | Mice, Knockout | Brain - drug effects | Algorithms | Animals | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Dogs | Protein Binding | Pyrimidines - pharmacokinetics | Mice | Benzamides | ATP Binding Cassette Transporter, Sub-Family B - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
by Baker, Sharyn D and Verweij, Jaap and Rowinsky, Eric K and Donehower, Ross C and Schellens, Jan H.M and Grochow, Louise B and Sparreboom, Alex
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias
by Singh, Renu and Mehrotra, Shailly and Gopalakrishnan, Mathangi and Gojo, Ivana and Karp, Judith E and Greer, Jacqueline M and Chen, Alice and Piekarz, Richard and Kiesel, Brian F and Gobburu, Jogarao and Rudek, Michelle A and Beumer, Jan H and ETCTN-6745 Study Team and ETCTN-6745 study team and on behalf of the ETCTN-6745 study team
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 02/2019, Volume 83, Issue 2, pp. 319 - 328
PurposeVeliparib is an oral inhibitor of poly(ADP-ribose) polymerase enzyme. Combination of veliparib and temozolomide was well-tolerated and demonstrated... 
Pharmacometrics | Exposure-response | Temozolomide | Veliparib | CANCER | PARP INHIBITOR | PREDICTION | TRIAL | POLYMERASE INHIBITOR ABT-888 | DNA-DAMAGING AGENTS | ONCOLOGY | OCT2 | TOPOTECAN | MASS | PHARMACOLOGY & PHARMACY | DRUG-DRUG INTERACTIONS | Antimitotic agents | Enzymes | Medical research | Analysis | Medicine, Experimental | Antineoplastic agents | Sugars | Monosaccharides | Creatinine | Mucositis | Toxicity | Myeloid leukemia | Leukemia | Body weight | Oral administration | Poly(ADP-ribose) | Poly(ADP-ribose) polymerase | Pharmacology | Exposure | Dosage | ADP | Survival | Patients | Optimization | Polymerase | Body mass | Ribose | Safety engineering | Safety | Pharmacokinetics | Acute myeloid leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Anti-cancer drug delivery using metal organic frameworks (MOFs)
by Ibrahim, Mihad and Sabouni, Rana and Husseini, Ghaleb A
Current Medicinal Chemistry, ISSN 0929-8673, 01/2017, Volume 24, Issue 2, pp. 193 - 214
Cancer is the uncontrolled growth of cells in the body and is considered as one of the major causes of death globally. There are several cytotoxic... 
Cytotoxicity | Chemotherapy | Metal organic frameworks (MOFs) | Loading | Release | Cancer | CANCER-CELLS | CHEMISTRY, MEDICINAL | CURCUMIN | release | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | ENCAPSULATION | SURFACE MODIFICATION | metal organic frameworks (MOFs) | loading | chemotherapy | ZEOLITIC IMIDAZOLATE FRAMEWORKS | NANOPARTICLES | THERAPY | PHARMACOLOGY & PHARMACY | cytotoxicity | TUMOR MICROENVIRONMENT | Humans | Succinates - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Organoplatinum Compounds - pharmacology | Drug Carriers | Nanoparticles | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacokinetics | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Busulfan - pharmacokinetics | Polymers - chemical synthesis | Doxorubicin - pharmacokinetics | Organometallic Compounds - chemical synthesis | Topotecan - pharmacokinetics | Cell Line, Tumor | Topotecan - administration & dosage | Organometallic Compounds - chemistry | Polymers - chemistry | Porosity | Fluorouracil - pharmacokinetics | Succinates - pharmacology
Journal Article
Details down arrow
6. Full Text The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models
by Pauline Breedveld and Dick Pluim and Greta Cipriani and Femke Dahlhaus and Maria A. J. van Eijndhoven and Cornelia J. F. de Wolf and Annemieke Kuil and Jos H. Beijnen and George L. Scheffer and Gerrit Jansen and Piet Borst and Jan H. M. Schellens
Molecular Pharmacology, ISSN 0026-895X, 01/2007, Volume 71, Issue 1, pp. 240 - 9
Some cellular uptake systems for (anti)folates function optimally at acidic pH. We have tested whether this also applies to efflux from cells by breast cancer... 
ATP Binding Cassette Transporter, Subfamily G, Member 2 | Cell Line | Rabbits | Humans | ATP-Binding Cassette Transporters/metabolism | Topotecan/pharmacokinetics | Mitoxantrone/pharmacokinetics | Animals | Antineoplastic Agents/pharmacokinetics | Biological Transport | Stilbenes/pharmacokinetics | Folic Acid/pharmacokinetics | Liver/metabolism | Dogs | Resveratrol | Cell Line, Tumor | Methotrexate/analogs & derivatives | Female | Kinetics | Neoplasm Proteins/metabolism | Breast Neoplasms/metabolism | Hydrogen-Ion Concentration | ANTIFOLATE RESISTANCE | ACQUIRED MUTATIONS | SUBSTRATE-SPECIFICITY | REDUCED FOLATE CARRIER | ABCG2 MULTIDRUG TRANSPORTER | INTRACELLULAR PH | PHARMACOLOGY & PHARMACY | BCRP/ABCG2 | TUMORS | CELL-LINE | CHEMOTHERAPEUTICS | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Liver - metabolism | Methotrexate - pharmacokinetics | Neoplasm Proteins - metabolism | Folic Acid - pharmacokinetics | Breast Neoplasms - metabolism | Topotecan - pharmacokinetics | ATP-Binding Cassette Transporters - metabolism | Stilbenes - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Mitoxantrone - pharmacokinetics | Methotrexate - analogs & derivatives
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1−/−/Mdr1a/1b−/− (triple-knockout) and wild-type mice
by Serena Marchetti and Nienke A. de Vries and Tessa Buckle and Maria J. Bolijn and Maria A.J. van Eijndhoven and Jos H. Beijnen and Roberto Mazzanti and Olaf van Tellingen and Jan H.M. Schellens
Molecular Cancer Therapeutics, ISSN 1535-7163, 08/2008, Volume 7, Issue 8, pp. 2280 - 2287
We tested whether erlotinib hydrochloride (Tarceva, OSI-774), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, is a substrate for... 
BCRP | pharmacokinetics | P-gp | MRP2 | bioavailability | erlotinib | CELL LUNG-CANCER | MULTIDRUG TRANSPORTER | GEFITINIB | METABOLISM | ONCOLOGY | MDR1A P-GLYCOPROTEIN | ORAL BIOAVAILABILITY | TOPOTECAN | TYROSINE KINASE INHIBITOR | DIETARY CARCINOGEN | CANCER RESISTANCE PROTEIN | Erlotinib Hydrochloride | Protein Kinase Inhibitors - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 | ATP Binding Cassette Transporter, Subfamily B - physiology | Quinazolines - pharmacokinetics | ATP-Binding Cassette Transporters - physiology | Mice, Knockout | ATP Binding Cassette Transporter, Subfamily B, Member 1 | Animals | ATP-Binding Cassette Transporters - genetics | Multidrug Resistance-Associated Proteins - physiology | Female | ATP Binding Cassette Transporter, Subfamily B - genetics | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy
by Zucker, Daniel and Andriyanov, Alexander V and Steiner, Ariel and Raviv, Uri and Barenholz, Yechezkel
Journal of Controlled Release, ISSN 0168-3659, 06/2012, Volume 160, Issue 2, pp. 281 - 289
Recently, developing drug delivery systems exhibiting controlled drug release at the tumor sites emerged as an attractive option for enhancing anticancer... 
Nanoliposomes | Therapeutic efficacy | Stability | Remote loading | Biodistribution | SAXS | STERICALLY STABILIZED LIPOSOMES | FLUORESCENCE POLARIZATION | DOXORUBICIN | ENCAPSULATION | TUMOR | X-RAY-SCATTERING | MODEL | FORMULATION | CHEMISTRY, MULTIDISCIPLINARY | DRUGS | PHARMACOLOGY & PHARMACY | RADIOFREQUENCY ABLATION | Nanoparticles - chemistry | Polyethylene Glycols - chemistry | Structure-Activity Relationship | Drug Carriers - chemistry | Tissue Distribution | Lipids - chemistry | Drug Storage | Surface Properties | Drug Compounding | Vincristine - administration & dosage | Vincristine - pharmacokinetics | Drug Stability | Solubility | Topotecan - therapeutic use | Particle Size | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Topotecan - pharmacokinetics | Vincristine - therapeutic use | Topotecan - administration & dosage | Mice | Liposomes | Delayed-Action Preparations | Drug Combinations | Drugs | Drug delivery systems | Care and treatment | Chemical properties | Health aspects | Polyols | Vehicles | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Clinical Pharmacokinetics of Intra-arterial Melphalan and Topotecan Combination in Patients with Retinoblastoma
by Taich, Paula, BSc and Ceciliano, Alejandro, MD and Buitrago, Emiliano, BSc and Sampor, Claudia, MD and Fandino, Adriana, MD and Villasante, Francisco, MD and Lucena, Evandro, MD and Romero, Livia, MD and Chantada, Guillermo L., MD, PhD and Schaiquevich, Paula, PhD
Ophthalmology, ISSN 0161-6420, 2014, Volume 121, Issue 4, pp. 889 - 897
Purpose To assess the antitumor activity, toxicity, and plasma pharmacokinetics of the combination of melphalan and topotecan for superselective ophthalmic... 
Ophthalmology | CARBOPLATIN | INTRAOCULAR RETINOBLASTOMA | MANAGEMENT | SOLID TUMORS | RADIATION-EXPOSURE | OPHTHALMOLOGY | PEDIATRIC-ONCOLOGY-GROUP | OPHTHALMIC ARTERY CHEMOTHERAPY | INFUSION | PHASE-I | CHILDREN | Prospective Studies | Humans | Retinoblastoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Retinal Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Chromatography, High Pressure Liquid | Retinoblastoma - metabolism | Retinoblastoma - pathology | Retinal Neoplasms - drug therapy | Melphalan - administration & dosage | Topotecan - pharmacokinetics | Melphalan - pharmacokinetics | Topotecan - administration & dosage | Female | Ophthalmic Artery - drug effects | Retinal Neoplasms - metabolism | Child | Infusions, Intra-Arterial | Retinoblastoma | Care and treatment | Melphalan
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood−Brain Barrier
by Poller, Birk and Wagenaar, Els and Tang, Seng Chuan and Schinkel, Alfred H
Molecular Pharmaceutics, ISSN 1543-8384, 04/2011, Volume 8, Issue 2, pp. 571 - 582
P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) combination knockout mice display disproportionately increased brain penetration... 
blood-brain barrier | ABCB1 | tyrosine kinase inhibitor | MDCKII | ABCG2 | PENETRATION | BIOAVAILABILITY | DISPOSITION | IN-VITRO | EFFLUX | PHARMACOKINETICS | TOPOTECAN | LINE | PHARMACOLOGY & PHARMACY | INHIBITORS | ACCUMULATION | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Niacinamide - analogs & derivatives | Topoisomerase I Inhibitors - pharmacokinetics | Pyrroles - pharmacokinetics | Humans | Neoplasm Proteins - physiology | Cells, Cultured | Pyridines - pharmacokinetics | Phenylurea Compounds | ATP-Binding Cassette Transporters - physiology | ATP-Binding Cassette, Sub-Family B, Member 1 - physiology | Blood-Brain Barrier - metabolism | Benzenesulfonates - pharmacokinetics | Animals | Biological Transport | Dogs | Topotecan - pharmacokinetics | Indoles - pharmacokinetics | ATP Binding Cassette Transporter, Sub-Family B | Antineoplastic Agents - pharmacokinetics | Mice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues
by Patel, Krupa J and Trédan, Olivier and Tannock, Ian F
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2013, Volume 72, Issue 1, pp. 127 - 138
Pharmacokinetic analyses estimate the mean concentration of drug within a given tissue as a function of time, but do not give information about the spatial... 
Medicine & Public Health | Drug distribution | Tumor microenvironment | Normal tissues | Oncology | Cancer Research | Topotecan | Pharmacology/Toxicology | Mitoxantrone | Doxorubicin | MOUSE PLASMA | SOLID TUMORS | TOPOISOMERASE-I | PENETRATION | CANCER | CHEMOTHERAPY | PHARMACOKINETICS | ONCOLOGY | BLOOD-VESSELS | ADRIAMYCIN | PHARMACOLOGY & PHARMACY | PHASE-I | Doxorubicin - blood | Neoplasms - metabolism | Topoisomerase I Inhibitors - metabolism | Liver - pathology | Kidney - blood supply | Kidney - pathology | Humans | Topotecan - metabolism | Antibiotics, Antineoplastic - blood | Coronary Vessels - metabolism | Neovascularization, Pathologic - pathology | Antineoplastic Agents - metabolism | Tissue Distribution | Kidney - metabolism | Liver - drug effects | Myocardium - metabolism | Female | Antineoplastic Agents - pharmacokinetics | Doxorubicin - metabolism | Topotecan - blood | Antibiotics, Antineoplastic - pharmacokinetics | Topoisomerase I Inhibitors - pharmacokinetics | Coronary Vessels - drug effects | Coronary Vessels - pathology | Kidney - drug effects | Mitoxantrone - metabolism | Mitoxantrone - blood | Liver - metabolism | Myocardium - pathology | Neoplasms - blood supply | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Neovascularization, Pathologic - drug therapy | Topotecan - pharmacokinetics | Antineoplastic Agents - blood | Cell Line, Tumor | Mice | Neovascularization, Pathologic - metabolism | Mitoxantrone - pharmacokinetics | Topoisomerase I Inhibitors - blood | Antibiotics, Antineoplastic - metabolism | Neoplasms - pathology | Anthracyclines | Care and treatment | Drug wholesalers | Analysis | Fluorescence | Tumors | Cancer | Index Medicus | Antitumor agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (–/–) MICE
by Shuzhong Zhang and Xiaodong Wang and Kazuko Sagawa and Marilyn E. Morris
Drug Metabolism and Disposition, ISSN 0090-9556, 03/2005, Volume 33, Issue 3, pp. 341 - 348
Breast cancer resistance protein (BCRP) is a recently identified ATP-binding cassette transporter, important in drug disposition and in the development of... 
QUERCETIN | LOCALIZATION | HEART-DISEASE | (ABCG2)-MEDIATED TRANSPORT | GENE | ORAL BIOAVAILABILITY | CELL LINE CACO-2 | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | P-GLYCOPROTEIN | ABCG2 | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Area Under Curve | ATP Binding Cassette Transporter, Sub-Family B - deficiency | Humans | Topotecan - antagonists & inhibitors | Biological Availability | Male | Neoplasm Proteins - antagonists & inhibitors | Drug Interactions | ATP-Binding Cassette Transporters - genetics | Female | Antineoplastic Agents - pharmacokinetics | Flavonoids - pharmacology | Topotecan - blood | Tetrahydroisoquinolines - pharmacology | Antineoplastic Agents - antagonists & inhibitors | Rats | Rats, Sprague-Dawley | Mice, Knockout | Animals | Benzoflavones - pharmacology | Acridines - pharmacology | Topotecan - pharmacokinetics | Antineoplastic Agents - blood | Cell Line, Tumor | Mice | ATP Binding Cassette Transporter, Sub-Family B - genetics | ATP-Binding Cassette Transporters - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
by Samol, Jens and Samol, Jens and Ranson, Malcolm and Ranson, Malcolm and Scott, Edwina and Scott, Edwina and Macpherson, Euan and Macpherson, Euan and Carmichael, James and Carmichael, James and Thomas, Anne and Thomas, Anne and Cassidy, James and Cassidy, James
Investigational New Drugs, ISSN 0167-6997, 8/2012, Volume 30, Issue 4, pp. 1493 - 1500
Background The aim of this phase I study was to determine the safety and tolerability and to establish the maximum tolerated dose (MTD) of orally administered... 
Medicine & Public Health | Targeted agents | PARP inhibitors | Oncology | Topotecan | Olaparib | Maximum tolerated dose | Pharmacology/Toxicology | DNA repair | SENSITIVITY | INDUCTION | CANCER | MAMMARY-TUMORS | ONCOLOGY | RESISTANCE | PHARMACOLOGY & PHARMACY | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Demography | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Topotecan - adverse effects | Treatment Outcome | Piperazines - therapeutic use | Neoplasms - diagnostic imaging | Topotecan - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Neoplasms - drug therapy | Maximum Tolerated Dose | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Aged | Phthalazines - adverse effects | Cohort Studies | Studies | Clinical trials | Inhibitor drugs | Drug therapy | Patients | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs
by Charlotte Kloft and Johan Wallin and Anja Henningsson and Etienne Chatelut and Mats O. Karlsson and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för farmaceutisk biovetenskap and Uppsala universitet and Avdelningen för farmakokinetik och läkemedelsterapi and Farmaceutiska fakulteten
Clinical Cancer Research, ISSN 1078-0432, 09/2006, Volume 12, Issue 18, pp. 5481 - 5490
Purpose: Cancer chemotherapy, although based on body surface area, often causes unpredictable myelosuppression, especially severe neutropenia. The aim of this... 
covariates | pharmacokinetic-pharmacodynamic modeling | dose individualization | cancer chemotherapy | subgroup identification | ETOPOSIDE | CANCER-PATIENTS | ONCOLOGY | BODY-SURFACE AREA | ORAL TOPOTECAN | PHASE-II | PROTEIN-BINDING | DOSE-INTENSITY | OVARIAN-CANCER | DOCETAXEL | CHEMOTHERAPY | Models, Theoretical | Etoposide - adverse effects | Liver - enzymology | Age Factors | Humans | Middle Aged | Neutrophils - drug effects | Paclitaxel - adverse effects | Topotecan - adverse effects | Male | Sex Characteristics | Liver - drug effects | Antineoplastic Agents - adverse effects | Drug Interactions - immunology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Neutropenia - chemically induced | Taxoids - adverse effects | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | FARMACI | Farmaceutiska vetenskaper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights